ArticleCancer science2009

Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, given weekly to advanced solid tumor patients for 3 weeks.

Nobuyuki Yamamoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.